4.3 Article

Sleep apnoea is a risk factor for severe COVID-19

Journal

BMJ OPEN RESPIRATORY RESEARCH
Volume 8, Issue 1, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjresp-2020-000845

Keywords

sleep apnoea; COVID-19

Funding

  1. Academy of Finland Center of Excellence in Complex Disease Genetics [312062, 312074]
  2. Finnish Foundation for Cardiovascular Research
  3. Sigrid Juselius Foundation
  4. University of Helsinki
  5. Juho Vainio Foundation
  6. Academy of Finland [309643, 340539]
  7. Oskar Offlund foundation
  8. Yrjo Jahnsson foundation
  9. Signe and Ane Gyllenberg foundation
  10. Instrumentarium science foundation
  11. HUCH research grant
  12. Business Finland [HUS 4685/31/2016, UH 4386/31/2016]
  13. AbbVie
  14. AstraZeneca UK
  15. Biogen MA
  16. Celgene Corporation
  17. Celgene International II Sarl
  18. Genentech
  19. Merck Sharp Dohme Corp
  20. Pfizer
  21. GlaxoSmithKline Intellectual Property Development
  22. Sanofi US Services
  23. Maze Therapeutics
  24. Janssen Biotech

Ask authors/readers for more resources

The study suggests that obstructive sleep apnoea (OSA) does not increase the risk of contracting COVID-19, but is associated with a higher risk of hospitalisation among COVID-19 positive patients.
Background Obstructive sleep apnoea (OSA) is associated with higher body mass index (BMI), diabetes, older age and male gender, which are all risk factors for severe COVID-19. We aimed to study if OSA is an independent risk factor for COVID-19 infection or for severe COVID-19. Methods OSA diagnosis and COVID-19 infection were extracted from the hospital discharge, causes of death and infectious diseases registries in individuals who participated in the FinnGen study (n=260 405). Severe COVID-19 was defined as COVID-19 requiring hospitalisation. Multivariate logistic regression model was used to examine association. Comorbidities for either COVID-19 or OSA were selected as covariates. We performed a meta-analysis with previous studies. Results We identified 445 individuals with COVID-19, and 38 (8.5%) of them with OSA of whom 19 out of 91 (20.9%) were hospitalised. OSA associated with COVID-19 hospitalisation independent from age, sex, BMI and comorbidities (p-unadjusted=5.13x10(-5), OR-adjusted=2.93 (95% CI 1.02 to 8.39), p-adjusted=0.045). OSA was not associated with the risk of contracting COVID-19 (p=0.25). A meta-analysis of OSA and severe COVID-19 showed association across 15 835 COVID-19 positive controls, and n=1294 patients with OSA with severe COVID-19 (OR=2.37 (95% 1.14 to 4.95), p=0.021). Conclusion Risk for contracting COVID-19 was the same for patients with OSA and those without OSA. In contrast, among COVID-19 positive patients, OSA was associated with higher risk for hospitalisation. Our findings are in line with earlier works and suggest OSA as an independent risk factor for severe COVID-19.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available